Anzeige
Mehr »
Lynx Broker
Login
Donnerstag, 17.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0NBFF ISIN: US6821431029 Ticker-Symbol: 3O8 
Tradegate
15.10.19
19:55 Uhr
13,995 Euro
+0,490
+3,63 %
1-Jahres-Chart
OMEROS CORPORATION Chart 1 Jahr
5-Tage-Chart
OMEROS CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
13,845
13,935
17:56
13,840
13,940
17:54

Aktuelle News zur OMEROS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.10.Omeros: No Partner - No Money8
OMEROS Aktien ab 5,00 US-Dollar handeln - Ohne versteckte Kosten!
16.09.Omeros up 2% on favorable safety data on addiction candidate4
11.09.Omeros to start rolling BLA submission for narsoplimab in Q44
12.08.Omeros: Moving Forward12
09.08.Omeros Corporation (OMER) CEO Greg Demopulos on Q2 2019 Results - Earnings Call Transcript4
08.08.Omeros EPS beats by $0.15, beats on revenue6
01.08.Lonza to continue narsoplimab manufacture for Omeros5
31.07.Omeros secures long-term production deal for OMS7214
31.07.Omeros, Lonza Enter Commercial Manufacturing Agreement1
31.07.OMEROS CORP - 8-K, Current Report1
31.07.Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab72Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros' lead human monoclonal antibody targeting...
► Artikel lesen
22.07.Omeros: The Commercial Prospects Remain Bright5
11.07.FDA on board with endpoint for pivot study of Omeros' narsoplimab; shares up 12% premarket10
27.06.Omeros: Full Steam Ahead7
11.06.OMEROS CORP - S-8, Securities to be offered to employees in employee benefit plans5
11.06.OMEROS CORP - 8-K, Current Report2
05.06.Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA59Preparations Continue for Submission of BLA in the U.S. and MAA in Europe Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has appointed...
► Artikel lesen
23.05.Omeros (OMER) Presents At UBS Global Healthcare Conference - Slideshow5
10.05.Omeros' (OMER) CEO Greg Demopulos on Q1 2019 Results - Earnings Call Transcript2
09.05.OMEROS CORP - 10-Q, Quaterly Report2
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1